Cover Image
市場調查報告書

前列腺肥大症:市場機會分析、預測 (∼2024年)

OpportunityAnalyzer: Benign Prostatic Hyperplasia - Opportunity Analysis and Forecast to 2024

出版商 GlobalData 商品編碼 346854
出版日期 內容資訊 英文 174 Pages
訂單完成後即時交付
價格
Back to Top
前列腺肥大症:市場機會分析、預測 (∼2024年) OpportunityAnalyzer: Benign Prostatic Hyperplasia - Opportunity Analysis and Forecast to 2024
出版日期: 2015年09月08日 內容資訊: 英文 174 Pages
簡介

全球主要市場 (美國、德國、法國、義大利、西班牙、英國、日本) 的2014年的前列腺肥大症 (BPH) 治療藥的銷售額估計約20億美元,預計到2024年,以8.23%的年複合成長率成長。預計前列腺內注射劑的NX-1207的銷售成為該市場的主要推動因素。

本報告提供前列腺肥大症 (BPH) 的治療藥相關趨勢調查、前列腺肥大症的概要與患病人數、目前主要BPH藥的產品簡介、未滿足需求與市場機會分析、開發平台趨勢、銷售額規模的變化與預測、市場促進因素&阻礙要素分析等彙整資料。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理生理學
  • 症狀、診斷
  • QoL (Quality of Life)

第4章 流行病學

  • 疾病的背景
  • 風險因素、並存症
  • 全球趨勢
    • 美國
    • 歐盟5國
    • 日本
  • 預測手法
  • BPH的流行病學的預測
    • 患病診斷數
    • 患病診斷數:各年齡
    • 患病診斷數:各重病度 (按照IPSS)
    • 年齡水平化患病診斷數 (%)
  • 討論
    • 流行病學的預測分析
    • 分析的規定
    • 分析的優勢

第5章 目前治療的選項

  • 概要
  • 主要BPH品牌的產品簡介
    • Flomax
    • Rapaflo
    • Uroxatral
    • 其他α1-腎上腺素受體拮抗劑
    • Finasteride
    • Avodart
    • Jalyn/Duodart
    • Cialis
    • Antimuscarinics
    • Phytotherapy
    • 醫療設備、外科的治療

第6章 未滿足需求、市場機會分析

  • 概要
  • 夜間頻尿症治療沒有有效藥物
    • 未滿足需求
    • 差距分析
    • 市場機會
  • BPH治療的患者多有性的不良影響
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 患者對BPH的認知度低
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 沒有可正確進行早期發現BPH的技術
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 沒有以BPH的原因為目標的治療藥
    • 未滿足需求
    • 差距分析
    • 市場機會
  • BPH相關醫生的教育貧弱
    • 未滿足需求
    • 差距分析
    • 市場機會

第7章 R&D策略

  • 概要
    • 排除性的不良影響
    • 新的投藥途徑
    • 二次適應症
    • 對患者的次級族群的標靶化
    • 授權契約、其他的聯盟
  • 臨床試驗設計
    • 目前臨床試驗
    • 未來的臨床試驗

第8章 開發平台評估

  • 概要
  • 在臨床開發中有前景的藥
    • NX-1207
    • PRX302
    • Vesomni
  • 初期階段的創新方法

第9章 開發平台評估分析

  • 主要開發平台藥物的臨床性基準
  • 主要開發平台藥物的商業性基準
  • 競爭評估
  • top line的10年預測
    • 美國
    • 歐盟5國
    • 日本
    • 成長推動因素、障礙

第10章 附錄

目錄
Product Code: GDHC040POA

GlobalData estimates the 2014 sales for the benign prostatic hyperplasia (BPH) therapeutics market at approximately $2 billion across the 7MM (US, Germany, France, Italy, Spain, UK and Japan). The US contributed a significant majority of these sales, generating an estimated $1.15 billion over the forecast period, ending in 2024. Benign Prostatic Hyperplasia therapeutics sales in the 7MM are expected to grow to $4.5 billion at a Compound Annual Growth Rate (CAGR) of 8.23%. The majority of sales in the 7MM in 2024 will come from the US, which will represent 65% of the market; with sales in the 5EU corresponding to 24%, while the remaining 12% in sales is attributable to Japan. The major driver for this growth across the 7MM will be the launch of NX-1207, a direct prostatic injection, which represents a first-in-class therapy for the treatment of moderate-to- severe BPH.

Highlights

Key Questions Answered

  • Overall, the greatest unmet need in the BPH space is the issue with hard to treat symptoms such as nocturia and the presence of sexual adverse effects that are common with BPH medications. There are other prominent unmet needs highlighted by the Key Opinion Leaders (KOLs). What are these? Will the pipeline drugs fulfil these unmet needs of the market?
  • The 10-year forecast period will mark the launch of three pipeline BPH drugs. How will the sales of the existing drugs be impacted? Which of the pipeline drugs will have the highest peak sales at the highest CAGR, and why?
  • Four BPH therapies will face patent expiration during the forecast period resulting in a therapy area dominated by generics. How will this affect the market size? How will pharmaceutical companies be affected and how can they hope to profit in this environment?

Key Findings

  • The major driver for growth in the BPH market during the forecast period will be the launch of three pipeline therapies which each represent an improvement over currently available medications in their own right. KOLs believe that the launch of NX-1207, PRX302 and Vesomni will considerably change the treatment algorithm for patients with BPH.
  • There are substantial unmet needs in the BPH area which need to be addressed. Targeting any of these unmet needs represents significant opportunities for investment in the area.
  • KOLs believe that BPH is an underappreciated disease and that there is the potential for momentous growth in the field.

Scope

  • Overview of BPH, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized BPH therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the BPH therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global BPH therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the BPH therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the BPH therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the 7MM BPH therapeutics market from 2014-2024.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms and Diagnosis
  • 3.3. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Japan
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods - Diagnosed Prevalent Cases
  • 4.5. Epidemiological Forecast for BPH (2014-2024)
    • 4.5.1. Diagnosed Prevalent Cases of BPH
    • 4.5.2. Age-Specific Diagnosed Prevalent Cases of BPH
    • 4.5.3. Diagnosed Prevalent Cases of BPH by Severity Using IPSS Criteria
    • 4.5.4. Age Standardized Diagnosed Prevalence of BPH (%)
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Current Treatment Options

  • 5.1. Overview
  • 5.2. Product Profiles of Major BPH Brands
    • 5.2.1. Flomax
    • 5.2.2. Rapaflo
    • 5.2.3. Uroxatral
    • 5.2.4. Other α1-adrenoceptor antagonists
    • 5.2.5. Finasteride
    • 5.2.6. Avodart
    • 5.2.7. Jalyn/Duodart
    • 5.2.8. Cialis
    • 5.2.9. Antimuscarinics
    • 5.2.10. Phytotherapy
    • 5.2.11. Medical Devices and Surgical Treatment

6. Unmet Needs Assessment and Oppportunity Analysis

  • 6.1. Overview
  • 6.2. There are No Effective Drugs for the Treatment of Nocturia
    • 6.2.1. Unmet need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Sexual Adverse Effects Encountered Frequently in Patients Receiving BPH Medication
    • 6.3.1. Unmet need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. There is a Lack of Patient Awareness of BPH
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. There are No Accurate Techniques for the Early Detection of BPH
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. There are No Drugs that Target the Cause of BPH
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Physician Education about BPH is Poor
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity

7. R&D Strategies

  • 7.1. Overview
    • 7.1.1. Eliminating Sexual Adverse Effects
    • 7.1.2. Novel Route of Administration
    • 7.1.3. Secondary Indications
    • 7.1.4. Targeting Patient Subgroups
    • 7.1.5. Licensing Agreements and Other Partnerships
  • 7.2. Clinical trial design
    • 7.2.1. Current Clinical Trials
    • 7.2.2. Future Clinical Trials

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. NX-1207
    • 8.2.2. PRX302
    • 8.2.3. Vesomni
  • 8.3. Innovative Early-stage Approaches

9. Pipeline Valuation Analysis

  • 9.1. Clinical Benchmark of Key Pipeline Drugs
  • 9.2. Commercial Benchmark of Key Pipeline Drugs
  • 9.3. Competitive Assessment
  • 9.4. Top Line Ten Year Forecast
    • 9.4.1. US
    • 9.4.2. 5EU
    • 9.4.3. Japan
    • 9.4.4. Drivers and Barriers

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4. Forecasting Methodology
    • 10.4.1. Diagnosed BPH patients
    • 10.4.2. Percent of Drug-treated Patients
    • 10.4.3. Drugs Included in Each Therapeutic Class
    • 10.4.4. Launch and Patent Expiry Dates
    • 10.4.5. General Pricing Assumptions
    • 10.4.6. Individual Drug Assumptions
    • 10.4.7. Generic Erosion
    • 10.4.8. Pricing of Pipeline agents
  • 10.5. Physicians and Specialists Included in this Study
  • 10.6. About the Authors
    • 10.6.1. Author
    • 10.6.2. Therapy Area Director
    • 10.6.3. Epidemiologist
    • 10.6.4. Global Head of Healthcare
  • 10.7. About GlobalData
  • 10.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Benign Prostatic Hyperplasia
  • Table 2: The International Prostate Symptoms Score (IPSS)
  • Table 3: Risk Factors and Comorbidities for BPH
  • Table 4: 7MM, Sources of Epidemiological Data Used in the Forecast for BPH Diagnosed Prevalence Data
  • Table 5: 7MM, Diagnosed Prevalent Cases of BPH, Ages ≥40 Years, Men (N), 2014-2024
  • Table 6: 7MM, Age-Specific Diagnosed Prevalent Cases of BPH, Ages ≥40 Years, Men, N (Row %), 2014
  • Table 7: Leading Treatments for BPH
  • Table 8: Product Profile - Flomax
  • Table 9: Flomax SWOT Analysis, 2015
  • Table 10: Product Profile - Rapaflo
  • Table 11: Rapaflo SWOT Analysis, 2015
  • Table 12: Product Profile - Uroxatral
  • Table 13: Uroxatral SWOT Analysis, 2015
  • Table 14: Product Profile - Proscar
  • Table 15: Proscar SWOT Analysis, 2015
  • Table 16: Product Profile - Avodart
  • Table 17: Avodart SWOT Analysis, 2015
  • Table 18: Product Profile - Jalyn
  • Table 19: Jalyn SWOT Analysis, 2015
  • Table 20: Product Profile - Cialis
  • Table 21: Cialis SWOT Analysis, 2015
  • Table 22: Overall Unmet Needs - Current Level of Attainment
  • Table 23: Clinical Trial Design of Key Marketed and Pipeline Drugs for Benign Prostatic Hyperplasia
  • Table 24: Inclusion and Exclusion Criteria Common in BPH Clinical Trials
  • Table 25: Benign Prostatic Hyperplasia - Late Stage Pipeline, 2015
  • Table 26: Product Profile - NX-1207
  • Table 27: NX-1207 SWOT Analysis, 2015
  • Table 28: Product Profile - PRX302
  • Table 29: PRX302 SWOT Analysis, 2015
  • Table 30: Product Profile - Vesomni
  • Table 31: Vesomni SWOT Analysis, 2015
  • Table 32: Early-stage Pipeline Products in Benign Prostatic Hyperplasia
  • Table 33: Clinical Benchmark of Key Pipeline Drugs
  • Table 34: Commercial Benchmark of Key Pipeline Drugs
  • Table 35: Top Line Sales Forecasts ($m) for Benign Prostatic Hyperplasia, 2014-2024
  • Table 36: Key Events That Will Impact Sales for Benign Prostatic Hyperplasia, 2014-2024
  • Table 37: Benign Prostatic Hyperplasia Market - Drivers and Barriers, 2014-2024
  • Table 38: Key Launch Dates
  • Table 39: Key Patent Expiries

List of Figures

  • Figure 1: A Graphical Representation of the Role of DHT in the Prostate
  • Figure 2: A Schematic Illustration of How an Imbalance of DHT Levels in the Prostate Disrupts the Growth Cycle
  • Figure 3: The Complex Relationship Between Neuroregulatory Factors and Benign Prostatic Hyperplasia
  • Figure 4: Anatomy of a Prostate Gland
  • Figure 5: The Management Protocol for Benign Prostatic Hyperplasia
  • Figure 6: 7MM, Diagnosed Prevalent Cases of BPH, Ages ≥40 Years, Men (N), 2014-2024
  • Figure 7: 7MM, Age-Specific Diagnosed Prevalent Cases of BPH, Ages ≥40 years, Men (N), 2014
  • Figure 8: 7MM, Severity Profile of Diagnosed Prevalent Cases of BPH, Ages ≥40 years, Men (N), 2014
  • Figure 9: 7MM, Age Standardized Prevalence of BPH, Ages ≥40 years, Men (%), 2014
  • Figure 10: The NO/cGMP Pathway
  • Figure 11: Mechanism of Action of PRX302
  • Figure 12: Competitive Assessment of Late-stage Pipeline Agents in Benign Prostatic Hyperplasia, 2014-2024
  • Figure 13: Sales for the Benign Prostatic Hyperplasia Market in the 7MM, 2014-2024
  • Figure 14: Global Sales of Benign Prostatic Hyperplasia Drugs by Region, 2014 and 2024
Back to Top